Always has been. Q4 and Q1 are the best 2 quarters for the market with Q3 being the weakest. Its easy to see when I look at a long term history of my performance on a quarterly basis. Q3 has been a down quarter by 1 -2% for years for me. That is why I lighten up after Q2 earnings and wait for a lower entry point.
Good thing is the patent problem is behind us. The bad is that earnings disappointed many analysts. Many expected the non Revlimid drugs to post much higher growth. This was a case of the analysts expected too much. I think we will spend much of Q2 in the penalty box. We will need to see Q2 earnings beat expectations now before analysts get back on the bandwagon. Got to remember big funds only care about making their quarter or their year. We as individuals have the luxury of looking at the long term like 20B in sales by 2020 and that GED-301 could be worth as much as Revlimid for sales by 2022. Unless we get some data that impresses analysts at ASCO or from a trail, I think CELG will still be unloved by big money.
the markets will take off in 2nd half of 2015 - that is what they say. so we have to endure few more weeks.
CELG definitely will fly with the markets then, if not by then. We need to see volumes.
BioLargo (BLGO) and Lockheed (LMT) have proven and game changing technologies to help create abundant water for everyone.
BioLargo’s breakthrough AOS Filter has been proven to decontaminate and disinfect water at unprecedented levels and speeds and cost 1/20th of the closest competing technology.
The AOS Filter is showcasing this August at the University of Alberta to huge industry leaders and is extremely close to commercialization while Lockheed’s Graphene Filter is about 3 to 5 years away.
To read report, copy and paste: Desalination Industry Screams for Cost Cutting Innovation: Lockheed And BioLargo Hold Key Technologies
BioLargo is Strong Buy with $3.00 12-month Price Target and significantly higher in coming years.
Sentiment: Strong Buy
Only a matter of time :)
will never see 118 in 10 lifetimesby get_rich_carefully •Dec 10, 2014 1:59 PM
get_rich_carefully get_rich_carefully • May 13, 2015 12:27 PM
How r we doing buying above 118
I have been in CELG for years. Their management has never failed to exceed any guidance they have set. All that time I have seen many doubters come and go. Short term traders talking about chart patterns and resistances. Truth is CELG has consistently proven the critics wrong. Yesterday they said GED-301 could be worth 7 Billion in sales in Crohn's and UC. As I look at the numbers, I can easily see that. Nearly 1.2 million people in US and Europe suffer from Crohn's. There is no real treatment for these patients. The current treatments are only 48% effective and lose effectiveness for 75% of patients within one year. Current treatments are injections and have many side affects. GED-301 is a pill and has 72% effectiveness. GED-301 had a safety profile equal to placebo which means little to no side affects. Current treatments go for up to 30k per year. Even at 20k per year with 1.2 million patient you get to 24B in revenues. I wouldn't expect full 100% market share, but at 50% market share they could easily get to 10 - 12 B in revenues. I know there are still phase 3 tests to get through, but if they go well, we could see fast track for GED-301 and it could come to market before expected in 2018. It completely blows my mind how people are so short sighted to care about the next quarter or a short term pattern on a chart to completely miss a 7 Billion dollar opportunity.
Sentiment: Strong Buy
Sunday, Celgene presented data for Morgesen (GED-301). It was a amazing presentation. They said they thought this drug could be worth at least 7 to 8 B in sales. That is huge and more then 2x what most analysts expected.
hey there rob, bermudagreek here, long long time, back when celg was flatlined in the mid 50s 6 yrs ago..
good call and great work ..
need info on xon, dividend of ziop .. how many shares do you get of ziop for owning 1 share of xon...
and also i see your likely crmd pulled back nicely...
what do you suggest of crmd ...
Every one wants to be a social media star. We all present a lot of information here to share thoughts with other holders. I don't think anyone lives under the misconception that their opinion makes a difference. Most of the posting here is moral support for us longs when the market is treating us bad.
Neglected the Disclosure. Buy and hold Long-Term. Sold at $108, hoping it will drop down a bit from today's $115 so I can hop back in...